---
url: https://www.servicesaustralia.gov.au/giant-cell-arteritis
title: Giant Cell Arteritis - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:40.336Z
source: servicesaustralia.gov.au
---
# Giant Cell Arteritis

The PBS subsidises tocilizumab for patients with active giant cell arteritis.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with tocilizumab under the _National Health Act 1953_, section 85 for patients aged 50 years or older with active giant cell arteritis (GCA).

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the PBS website outlines the restrictions for prescribing tocilizumab.

## Treatment specifics

To be eligible for PBS-subsidised treatment with tocilizumab, patients must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of active GCA.

A patient may only qualify for PBS-subsidised treatment with tocilizumab for active GCA once in a lifetime. The treatment mustn’t exceed 52 weeks in total including initial and continuing applications.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised tocilizumab to treat active GCA can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [giant cell arteritis - tocilizumab - initial authority application form](/pb272?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised tocilizumab to treat active GCA can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
